Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Mini-Review

Avoiding hepatic veno-occlusive disease: what do we know and where are we going?

Bone Marrow Transplantation volume 27, pages 1113–1120 (2001)Cite this article

Abstract

Hepatic venocclusive disease (VOD) is a common toxicity associated with myeloablative chemotherapy or chemoradiotherapy used to prepare patients for stem cell transplantation. A sizable proportion of patients who develop VOD die. It is clear that injury to endothelial cells and hepatocytes in zone 3 of the liver acinus is the initial event in the pathogenesis of VOD. What are less clear are the mechanisms of injury and whether this knowledge can be exploited. This manuscript will briefly review some recent data and discuss how that information has influenced clinical practice. Bone Marrow Transplantation (2001) 27, 1113–1120.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Bearman SI . The syndrome of hepatic veno-occlusive disease after marrow transplantation Blood 85: 1995 3005–3020

    CAS  PubMed  Google Scholar 

  2. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Int Med 1993 118: 255–267

    Article  CAS  PubMed  Google Scholar 

  3. Toh HC, McAfee SL, Sackstein R et al. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation Bone Marrow Transplant 1999 24: 891–895

    Article  CAS  PubMed  Google Scholar 

  4. Lee JL, Gooley T, Bensinger W et al. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome Biol Blood Marrow Transplant 1999 5: 306–315

    Article  CAS  PubMed  Google Scholar 

  5. Bearman SI, Anderson G, Mori M et al. Venocclusive disease of the liver. Development of a model for predicting fatal outcome after marrow transplantation J Clin Oncol 1993 11: 1729–1736

    Article  CAS  PubMed  Google Scholar 

  6. Richardson PG, Elias AD, Krishnan A et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in efficacy without significant toxicity in a high risk population Blood 1998 92: 737–744

    CAS  PubMed  Google Scholar 

  7. Shulman HM, Fisher LB, Schoch HG et al. Venocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms Hepatol 1994 19: 1171–1181

    Article  CAS  Google Scholar 

  8. Gordon B, Tarantolo S, Ruby E et al. Increased platelet transfusion requirement is associated with multiple organ dysfunctions in patients undergoing hematopoietic stem cell transplantation Bone Marrow Transplant 1998 22: 999–1003

    Article  CAS  PubMed  Google Scholar 

  9. Oh H, Tahara T, Bouvier M et al. Plasma thrombopoietin levels in marrow transplant patients with veno-occlusive disease Bone Marrow Transplant 1998 22: 675–679

    Article  CAS  PubMed  Google Scholar 

  10. Gumucio JJ, Chianale J . Liver cell heterogeneity and liver function. In: Arias IM, Jakoby WP, Popper H et al. (eds) The Liver: Biology and Pathobiology, 2nd edn Raven: New York 1988 pp 931–947

    Google Scholar 

  11. el Mouelhi M, Kauffman FC . Sublobular distribution of transferases and hydrolases associated with glucuronide, sulfate and glutathione conjugation in human liver Hepatol 6: 1986 450–456

    Article  CAS  Google Scholar 

  12. DeLeve LD . Dacarbazine toxicity in murine liver cells: a model of hepatic endothial injury and glutathione defense J Pharm Exp Ther 1994 286: 1261–1270

    Google Scholar 

  13. DeLeve LD . Cellular target of cyclophosphamide toxicity in murine liver: role of glutathione and site of metabolic activation Hepatol 1996 24: 830–837

    Article  CAS  Google Scholar 

  14. Wang X, Kanel GC, DeLeve LD . Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat Hepatol 2000 31: 428–434

    Article  CAS  Google Scholar 

  15. Ringden O, Remberger M, Lehmann S et al. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation Bone Marrow Transplant 2000 25: 993–996

    Article  CAS  PubMed  Google Scholar 

  16. Hong RW, Rounds JD, Helton WS et al. Glutamine preserves liver glutathione after lethal hepatic injury Ann Surg 1992 215: 114–119

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Goringe AP, Brown S, O'Callaghan U et al. Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy Bone Marrow Transplant 1998 21: 829–832

    Article  CAS  PubMed  Google Scholar 

  18. Brown SA, Goringe A, Fegan C et al. Parenteral glutamine protects hepatic function during bone marrow transplantation Bone Marrow Transplantation 1998 22: 281–284

    Article  CAS  PubMed  Google Scholar 

  19. Shulman HM, Gown AM, Nugent DJ . Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded centralvenules Am J Pathol 1987 127: 549–558

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Faioni EM, Krachmalnicoff A, Bearman SI et al. Naturally occuring anticoagulants and bone marrow transplantation: Plasma protein C predicts development of venocclusivedisease of the liver Blood 1993 81: 3458–3462

    CAS  PubMed  Google Scholar 

  21. Tanikawa S, Mori S, Ohhashi K et al. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study Bone Marrow Transplant 2000 26: 881–886

    Article  CAS  PubMed  Google Scholar 

  22. Gordon BG, Haire W, Kessinger A et al. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma Bone Marrow Transplant 1991 8: 497–502

    CAS  PubMed  Google Scholar 

  23. Haire WD, Ruby EI, Gordon BG et al. Multiple organ dysfunction syndrome in bone marrow transplantation J Am Med Assoc 1995 274: 1289–1295

    Article  CAS  Google Scholar 

  24. Lee J-H, Lee K-H, Kim S et al. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study Bone Marrow Transplant 1998 22: 883–888

    Article  CAS  PubMed  Google Scholar 

  25. Catani L, Gugliotta L, Mattioli Belmonte M et al. Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies Bone Marrow Transplant 1993 12: 253–259

    CAS  PubMed  Google Scholar 

  26. Harper PL, Jarvis J, Jennings I et al. Changes in the natural anticoagulants following bone marrow transplantation Bone Marrow Transplantation 1990 5: 39–42

    CAS  PubMed  Google Scholar 

  27. Sudhoff T, Heins M, Sohngen D et al. Plasma levels of D-dimer and circulating endothelial adhesion molecules in veno-occlusive disease of the liver following allogeneic bone marrow transplantation Eur J Haematol 1998 60: 106–111

    Article  CAS  PubMed  Google Scholar 

  28. Ganem G, Saint-Marc Girardin M-F, Kuentz M et al. Venocclusive disease of the liver after allogeneic bone marrow transplantation in man Int J Radiat Oncol Biol Phys 1998 14: 879–884

    Article  Google Scholar 

  29. Nevill TJ, Barnett MJ, Klingemann H-G et al. Regimen-related toxicity of a bulsulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation J Clin Oncol 1991 9: 1224–1232

    Article  CAS  PubMed  Google Scholar 

  30. Rosing J, Tans G . Effects of oral contraceptives on hemostasis and thrombosis Am J Obstet Gynecol 180: S375–S382

    Article  CAS  PubMed  Google Scholar 

  31. Hägglund H, Remberger M, Klaesson S et al. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation Blood 1998 92: 4568–4572

    PubMed  Google Scholar 

  32. Bearman SI, Hinds MS, Wolford JL et al. A pilot study of continuous infusion heparin for the prevention of hepatic venocclusive disease after bone marrow transplantation Bone Marrow Transplant 1990 5: 407–411

    CAS  PubMed  Google Scholar 

  33. Marsa-Vila L, Gorin NC, Laport JP et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation Eur J Haematol 1991 47: 346–354

    Article  CAS  PubMed  Google Scholar 

  34. Attal M, Huguet F, Rubie H et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. 1992 Blood 79: 2834–2840

  35. Rosenthal J, Sender L, Secola R et al. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation Bone Marrow Transplant 1996 18: 185–191

    CAS  PubMed  Google Scholar 

  36. Or R, Nagler A, Shpilberg O et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients Transplantation 1996 61: 1067–1071

    Article  CAS  PubMed  Google Scholar 

  37. Bearman SI, Lee JL, Baron AE, McDonald GB . Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients Blood 1997 89: 1501–1506

    CAS  PubMed  Google Scholar 

  38. Schriber J, Milk B, Shaw D et al. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation Bone Marrow Transplant 1999 24: 1311–1314

    Article  CAS  PubMed  Google Scholar 

  39. Morris JD, Harris RE, Hashmi R et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation Bone Marrow Transplant 1997 20: 871–878

    Article  CAS  PubMed  Google Scholar 

  40. Mertens R, Brost H, Granzen B, Nowak-Gottl U . Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer Eur J Pediatr 1999 158: (Suppl. 3) S154–S158

    Article  CAS  PubMed  Google Scholar 

  41. Richardson PG, Murakami C, Warren DL et al. Multi-institutional emergency use of defibrotide in 75 patients post SCT with severe VOD and multisystem organ failure: Response without significant toxicity in a high risk population Blood 2000 96: (Suppl. 1) 2510

    Google Scholar 

  42. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation of veno-occlusive disease in patients undergoing bone marrow transplantation Cancer Chemother Pharmacol 1989 25: 55–61

    Article  CAS  PubMed  Google Scholar 

  43. Dix SP, Wingard JR, Mullins RE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT Bone Marrow Transplant 1996 17: 225–230

    CAS  PubMed  Google Scholar 

  44. Ljungman P, Hassan M, Bekassy AN et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients Bone Marrow Transplant 1997 20: 909–913

    Article  CAS  PubMed  Google Scholar 

  45. Slattery JT, Sanders JE, Buckner CD et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 1995 16: 31–42

    CAS  PubMed  Google Scholar 

  46. Vassal G, Koscielny S, Challine D et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation Cancer Chemother Pharmacol 1996 37: 247–253

    Article  CAS  PubMed  Google Scholar 

  47. Slattery JT, Kalhorn TF, McDonald GB et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients J Clin Oncol 1996 14: 1484–1494

    Article  CAS  PubMed  Google Scholar 

  48. Andersson BS, Madden T, Tran HT et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study Biol Blood Marrow Transplant 2000 6: 548–554

    Article  CAS  PubMed  Google Scholar 

  49. Vaughan WP, Cagnoni P, Fernandez H et al. Decreased incidence of and risk factors for hepatic veno-occlusive disease with an intravenous busulfan containing preparative regimen for hematopoietic stem cell transplantation Blood 1998 92: (Suppl. 1) 516a

    Google Scholar 

  50. Holler E, Kolb H-J, Moller A et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation Blood 1990 75: 1011–1016

    CAS  PubMed  Google Scholar 

  51. Ferra C, de Sanjose S, Lastra CF et al. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications Bone Marrow Transplant 1997 20: 1075–1080

    Article  CAS  PubMed  Google Scholar 

  52. Tanaka J, Imamura M, Kasai M et al. Cytokine gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation Br J Haematol 1993 85: 558–565

    Article  CAS  PubMed  Google Scholar 

  53. Remberger M, Ringden O . Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation Transplantation 1995 60: 1293–1299

    Article  CAS  PubMed  Google Scholar 

  54. Khoury H, Adkins D, Brown R et al. Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity? Bone Marrow Transplant 2000 25: 737–743

    Article  CAS  PubMed  Google Scholar 

  55. Testa S, Manna A, Porcellini A et al. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation Bone Marrow Transplant 1996 18: 383–388

    CAS  PubMed  Google Scholar 

  56. Catani L, Gugliotta L, Vianelli N et al. Endothelium and bone marrow transplantation Bone Marrow Transplant 1996 17: 277–280

    CAS  PubMed  Google Scholar 

  57. Richardson P, Hoppensteadt D, Elias A et al. Elevation of tissue factor pathway inhibitor (TFPI), thrombomodulin (TM) and plasminogen activator inhibitor-1 (PAI-1) levels in stem cell transplant (SCT)-associated veno-occlusive disease Blood 1997 90: (Suppl. 1) 219a

    Google Scholar 

  58. Salat C, Holler E, Reinhardt B et al. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease Bone Marrow Transplant 1994 14: 747–750

    CAS  PubMed  Google Scholar 

  59. Salat C, Holler E, Kolb H-J et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation Blood 1997 89: 2184–2188

    CAS  PubMed  Google Scholar 

  60. Richard S, Seigneur M, Blann A et al. Vascular endothelial lesion in patients undergoing bone marrow transplantation Bone Marrow Transplant 1996 18: 955–959

    CAS  PubMed  Google Scholar 

  61. Crawford SW, Fisher L . Predictive value of pulmonary function tests before marrow transplantation Chest 1992 101: 1257–1264

    Article  CAS  PubMed  Google Scholar 

  62. Manute-Bello G, McDonald GB, Hinds MS et al. Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation Bone Marrow Transplant 1998 21: 1125–1130

    Article  Google Scholar 

  63. Friedman SL . The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies New Engl J Med 1993 328: 1828–1835, 1993

    Article  CAS  PubMed  Google Scholar 

  64. Scanga AE, Schrum LW, Iozzo RV et al. Transcriptional regulation of the biglycan gene Hepatol 1997 26: (Suppl.) 597A

    Google Scholar 

  65. Sato Y, Asada Y, Hara S et al. Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation Histopathology 1999 34: 66–70

    Article  CAS  PubMed  Google Scholar 

  66. Eltumi M, Trivedi P, Hobbs JR et al. Monitoring of veno-occlusive disease after bone marrow transplantation by serum amino-propeptide of type III procollagen Lancet 1993 342: 518–521

    Article  CAS  PubMed  Google Scholar 

  67. Heikinheimo M, Halili R, Fasth A . Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation Blood 1994 83: 3036–3040

    CAS  PubMed  Google Scholar 

  68. Rio B, Bauduer F, Arrago JP, Zittoun R . N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin Bone Marrow Transplant 1993 11: 471–472

    CAS  PubMed  Google Scholar 

  69. Schuppan D, Farrand A, Oesterling C et al. Circulating markers of hepatic fibrosis predict evolution of venocclusive disease after marrow transplantation Hepatol 1997 26: (Suppl.) 452A

    Google Scholar 

  70. Cavet J, Middleton PG, Segall M et al. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants Blood 1999 94: 3941–3446

    CAS  PubMed  Google Scholar 

  71. Haire WD, Cavet J, Pavletic SZ et al. Tumor necrosis factor d3 allele predicts for organ dysfunction after allogeneic blood stem cell transplantation Blood 2000 96: (Suppl. 1) 584a

    Google Scholar 

  72. Essell JH, Schroeder MT, Harman GS et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial Ann Intern Med 1998 128: 975–981

    Article  CAS  PubMed  Google Scholar 

  73. Ohashi K, Tanabe J, Watanabe R et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation Am J Hematol 2000 64: 32–38

    Article  CAS  PubMed  Google Scholar 

  74. Ishida H, Nakayasu H, Nukaya H, Tsuji K . Study of the pharmacological effect of the bile salt, sodium scymnol sulfate, from Rhizopriondon acutus. II. Prophylactic effect of scymnol on lesion development in a rat peripheral arterial occlusion model Biol Pharm Bull 1998 21: 240–244

    Article  CAS  PubMed  Google Scholar 

  75. Neuman MG, Shear NH, Bellentani S, Tiribelli C . Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells Gastroenterol 1998 115: 157–166

    Article  CAS  Google Scholar 

  76. Fried MW, Connaghan DG, Sharma S et al. Transjugular intrahepatic portosystemic shunt for the management of severe venocclusive disease following bone marrow transplantation Hepatol 1996 24: 588–591

    Article  CAS  Google Scholar 

  77. de la Rubia J, Carral A, Montes H et al. Successful treatment of hepatic veno-occlusive disease in a peripheral blood progenitor cell transplant patient with a transjugular intrahepatic portosystemic stent-shunt (TIPS) Haematologica 1996 81: 536–539

    CAS  PubMed  Google Scholar 

  78. Smith FO, Johnson MS, Scherer LR et al. Transjugular intrahepatic portosystemic shunting (TIPS) for treatment of severe hepatic veno-occlusive disease Bone Marrow Transplant 1996 18: 643–646

    CAS  PubMed  Google Scholar 

  79. Azoulay D, Castaing D, Lemoine A et al. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation Bone Marrow Transplant 2000 25: 987–992

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Dr Bearman is the recipient of a Midcareer Investigator Award in Patient-Oriented Research (1K24 CA81408) from the National Cancer Institute.

Author information

Authors and Affiliations

  1. Bone Marrow Transplant Program, University of Colorado Health Sciences Center, Denver, CO, USA

    SI Bearman

Authors
  1. SI Bearman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bearman, S. Avoiding hepatic veno-occlusive disease: what do we know and where are we going?. Bone Marrow Transplant 27, 1113–1120 (2001). https://doi.org/10.1038/sj.bmt.1703014

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703014

Keywords

This article is cited by

Search

Advanced search

Quick links